Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR.From December 2003 to August 2005, 572 pat ...

Patients were required to have EGFr expression demonstrated on formalin-fixed paraffin-embedded tumor tissue by immunohistochemical staining before study participation. Patients were required to have ...

Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) have a poor prognosis, particularly those whose disease has progressed on previous platinum ...

In addition, cetuximab-resistant cells manifested strong activation of HER2, HER3 and cMET. ... Using immunofluorescent staining, ...

An exploratory analysis of E5397, a randomized first-line study comparing cisplatin with cisplatin plus cetuximab in squamous cell carcinoma of the head and neck, suggested that the treatment effect ...

The addition of cetuximab to radiotherapy appeared to improve clinical outcomes for patients with locoregionally advanced oropharyngeal cancer, regardless of HPV or p16 status, according to a ...

Cetuximab is a monoclonal an ... The degree of EGFR expression, either as the percentage of EGFR-positive tumor cells or as the maximal staining intensity per cell, ...

Cetuximab binds to EFGR to stop the downstream protein signalling that promotes cancer growth. Currently, it is licensed for use as a first-line drug in patients with advanced cancer as well as a ...

Cetuximab (Erbitux) plus chemotherapy showed higher progression-free survival (PFS) and overall survival (OS) for patients with metastatic colorectal cancer (mCRC), according to one study.

The monoclonal antibody cetuximab (Erbitux) was more effective than a newer drug, the immune checkpoint inhibitor medicine durvalumab (Imfinzi), in fighting head-and-neck tumors, the trial found.

Cetuximab is a monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR) which is present on the surface of some cancer cells. Cetuximab binds to the receptor, preventing ...